ERBB2 and breast cancer: Not only does targeted therapy (trastuzumab, pertuzumab, and TDM-1) depend on the diagnosis of HER2 status, but the HER2 status also affects the chemotherapy strategy for breast cancer (Gradishar et al., 2020).